8-K: Athira Pharma Faces Nasdaq Delisting Notice Due to Low Share Price, Plans New $300 Million Shelf Registration

Athira Pharma received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, while also planning to file a new $300 million shelf registration.

Summary

• Athira Pharma has been notified by Nasdaq that its stock price has fallen below the required minimum of $1.00 per share for 30 consecutive business days.
• The company has until April 14, 2025, to regain compliance by maintaining a share price of at least $1.00 for a minimum of 10 consecutive business days.
• If Athira fails to meet this deadline, it may be eligible for an additional 180 days by transferring to the Nasdaq Capital Market, provided it meets other listing requirements.
• The company intends to file a new registration statement on Form S-3 to replace its expiring shelf registration, allowing it to offer up to $300 million in securities.
• There is no guarantee that Athira will regain compliance with Nasdaq listing requirements or successfully access the capital markets.

Sentiment

Score: 3

Explanation: The document contains negative news regarding a delisting notice, but also includes a plan for a new shelf registration, which provides some hope for the future. Overall, the sentiment is negative due to the delisting risk.

Positives

• Athira has an initial 180-day period to regain compliance with Nasdaq's minimum bid price requirement.
• The company may be eligible for an additional 180-day compliance period by transferring to the Nasdaq Capital Market.
• The new $300 million shelf registration provides financial flexibility for the next three years.

Negatives

• Athira's stock price has fallen below the minimum bid price requirement of $1.00 per share.
• There is no guarantee that the company will regain compliance with Nasdaq listing requirements.
• The company may face delisting if it fails to meet the minimum bid price requirement within the given timeframes.

Risks

• The company may not be able to regain compliance with the minimum bid price requirement by the deadline.
• Athira may not qualify for an additional compliance period or may fail to regain compliance during the second period.
• There is a risk that the company may be delisted from Nasdaq.
• The company may not be able to successfully access the capital markets through the new registration statement.
• The proposed registration statement on Form S-3 may not be declared effective.

Future Outlook

The company intends to regain compliance with Nasdaq listing requirements and access capital markets through a new shelf registration. However, there is no guarantee of success.

Management Comments

• The Company intends to actively monitor the closing bid price of its Common Stock and will consider all available options to regain compliance with the Minimum Bid Price Requirement, which may include seeking stockholder approval to effect a reverse stock split.

Industry Context

The delisting notice highlights the challenges faced by biotech companies with volatile stock prices, especially those in the development stage. It is not uncommon for companies to face delisting notices and seek to regain compliance through various measures.

Comparison to Industry Standards

• Many biotech companies, particularly those with pre-revenue or early-stage clinical programs, experience stock price volatility and can fall below the Nasdaq minimum bid price requirement.
• Companies like Cassava Sciences (SAVA) and Amylyx Pharmaceuticals (AMLX) have also experienced significant stock price fluctuations, although they have not faced delisting notices recently.
• The use of shelf registrations to raise capital is a common practice in the biotech industry, allowing companies to access funds as needed.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment value.
• Employees may experience uncertainty due to the company's financial challenges.
• The company's ability to fund research and development may be impacted.

Next Steps

• Athira will actively monitor its stock price and consider options to regain compliance, including a potential reverse stock split.
• The company will file a registration statement on Form S-3.
• Athira will seek to maintain compliance with Nasdaq listing requirements.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, shelf registration, capital markets, reverse stock split, ATHA, Form S-3